| 35.95 1.92 (5.64%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 42.35  |
1-year : | 49.46 |
| Resists | First : | 36.25 |
Second : | 42.35 |
| Pivot price | 30.99 |
|||
| Supports | First : | 28.37 |
Second : | 23.5 |
| MAs | MA(5) : | 32.37 |
MA(20) : | 30.02 |
| MA(100) : | 26.55 |
MA(250) : | 21.78 |
|
| MACD | MACD : | 1.9 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 86.9 |
D(3) : | 79.9 |
| RSI | RSI(14): 74.9 |
|||
| 52-week | High : | 36.25 | Low : | 9.85 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SEPN ] has closed above the upper band by 20.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 37.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.31 - 36.45 | 36.45 - 36.59 |
| Low: | 33.5 - 33.66 | 33.66 - 33.8 |
| Close: | 35.69 - 35.94 | 35.94 - 36.19 |
Septerna, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the identification and advancement of orally administered, small molecule therapies that modulate G protein-coupled receptors (GPCRs). The company's pipeline is designed to address a spectrum of conditions within endocrinology, immunology and inflammation, and metabolic disorders. Among its key programs, Septerna is developing SEP-786, an oral small molecule serving as a PTH1R agonist for individuals suffering from hypoparathyroidism. Another candidate, SEP-631, is an oral small molecule MRGPRX2 NAM aimed at treating chronic spontaneous urticaria and other mast cell-related ailments. Furthermore, its TSHR Program involves an oral small molecule TSHR NAM for both Graves' disease and thyroid eye disease. The company is also progressing oral small molecule single- and multi-incretin receptor agonists to tackle metabolic issues such as obesity and type 2 diabetes. Founded in 2019, Septerna, Inc. is headquartered in South San Francisco, California. It was formerly known as GPCR NewCo, Inc. until its rebranding to Septerna Inc. in June 2021.
Fri, 12 Jun 2026
SEPN: 8,428 shares proposed sale; Samira Shaikhly 10b5-1 sales listed - Stock Titan
Wed, 10 Jun 2026
Did SEP-479’s Endocrine Society Spotlight Just Shift Septerna’s (SEPN) Hypoparathyroidism Investment Narrative? - simplywall.st
Mon, 08 Jun 2026
Experimental oral hypoparathyroidism drug SEP-479 gets ENDO 2026 stage - Stock Titan
Sun, 07 Jun 2026
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wed, 03 Jun 2026
Septerna (SEPN) CPO sells 5,935 shares under Rule 10b5-1 plan - Stock Titan
Thu, 21 May 2026
New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN) - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 2.312e+007 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 2,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.656e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -49.9 % |
| Operating Margin | -50.2 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -9.3 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 108 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.39e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|